Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof

US10633426B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• Eureka Therapeutics, Inc. · US

Inventors

• Renier J. Brentjens · New York, US
• Eric Smith · New York, US
• Cheng Liu · Richmond, US

Key dates

• Filing date: Jun 5, 2017
• Grant date: Apr 28, 2020
• Expiry date: Sep 20, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.